In the January 2006 issue, the footnote to Table 1 appeared as " a N-terminal pro-brain natri uretic peptide has been approved by the FDA for risk-stratification purposes in acute coronary syndromes and recently also for riskstratification purposes in patients with stable coronary artery disease". a N-terminal pro-brain natriuretic peptide has been approved by the FDA for risk-stratification purposes in acute coronary syndromes and recently also for risk-stratification purposes in patients with stable coronary artery disease. BNP, brain natriuretic peptide; CD40L, CD40 ligand; CHF, congestive heart failure; CK-MB, creatine kinase MB; cTnI/T, cardiac troponin I or T; hsCRP, high-sensitivity C-reactive protein; IMA, ischemia-modified albumin; MI, myocardial infarction; MPO, myelopyroxidase; NT-proBNP, N-terminal pro-brain natriuretic peptide; RI, recurrent infarction.
